Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Janux Therapeutics (JANX) Gains from Sales and Divestitures (2024 - 2025)

Janux Therapeutics (JANX) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $15588.0 as the latest value for Q4 2025.

Quarterly Gains from Sales and Divestitures rose 523.52% to $15588.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15588.0 through Dec 2025, up 523.52% year-over-year, with the annual reading at $15588.0 for FY2025, 523.52% up from the prior year.
Gains from Sales and Divestitures for Q4 2025 was $15588.0 at Janux Therapeutics, up from $10275.0 in the prior quarter.
The five-year high for Gains from Sales and Divestitures was $15588.0 in Q4 2025, with the low at $2500.0 in Q3 2024.